Okay, great. Thank you so much for that update, Dr. El-Sayed. So we're going to just go over some of the questions briefly. The first question is recommendation 5.22. What is considered short-term? And this recommendation is in regards to non-nutritive sweeteners can be used instead of sugar-sweetened products in moderation and for short-term to reduce overall calorie and carbohydrate intake. In the recommendation, yeah, just what is considered moderation and for short-term. So it's very hard to tell what moderation or short-term is. But the message we want to send is, would you pick, like, say you have a person in clinic and they want a soda versus something that has, you know, one of these sweeteners. And basically the idea is, one is I don't want you to do either, if possible. But if you really are to do it, then I'll allow you to do it until we hopefully cut down and we start negotiating and then, you know, stop altogether. There isn't a defined long-term from these studies. It is just, you know, sort of a pragmatic approach. Wonderful. Thank you. The next question is from Connie. I am trained in BIH, but how can I incorporate it to my daily workflow so it counts as part of my consults? BIH, I'm sorry, I'm getting old. What's the acronym for? I am not too clear. I may need to clarify with Connie. Connie, can you teach me something today? Yeah, both of us. Yeah, we can move to the next question until Connie puts it in the chat, please. Now I'm going to Google it, Connie, if you don't mind. I know, I was Googling it. I'm going to put it in German. Melissa is saying that those strategies are also a part of DSMES. So thank you for adding that. There is a question, Dr. Zeng, I'm just seeing the chat here. Some people are asking questions like, you know, GLP-1 is for type 1. So in the standards, we cannot make recommendations for something that's not FDA approved? That's just a big question. I know that it's being used off-label. I don't think that I think that's, you know, fine clinically to do. But that was not FDA approved. So that is not something that can become standard of care until it's FDA approved. Yeah, it looks like there are several questions about lack of insurance coverage for incretins and SGLT-2, if you can speak on that. Yes, absolutely. So, I mean, it is a big problem. But where we stand, you know, from a standards of care perspective, you see, if we don't put it in the standards of care, it will not exist. It will not go anywhere. So we call our team as like the beginning of the line. And then we go from there to implementation of the guidelines. And then we work with advocacy groups. And we work with people in clinics to also advocate for an innovation to go from being an innovation to become mainstream. It takes 17 years. But we do not want to wait this long for things like GLP-1s and GLP-GIP or anything that is of proven benefit like technology or anything like that. So again, we are the beginning of the line. We work on implementation. I have teams who work on that. And of course, we interface with our great advocacy team at ADA to help that change. Wonderful. And here's actually looks like a very kind of a hot question in clinical practice. Can you comment on the transition strategies for glycemic control, if the patient needs to hold GLP-1s for seven days before a surgery? So this is tackled, I believe, in the text. So these medications have long half-lives. And, you know, if you look at, I mean, there's a lot of data that, you know, on a population level, that our worry is that people would have a complication during surgery or during, it's really case by case basis. That's number one. You know, we don't know what the procedure is, how long it is. But holding a week before is what currently people are recommending. Do we have very, very strong evidence based on? We do not. We do not. I mean, but this is the current, most appropriate recommendation that I would give you. Thank you so much. I think that's all the questions that we'll have time for today. Thank you so much, Dr. El-Sayed, for your presentation. We just want to wrap up with a few reminders before we conclude today. If you haven't already done so, we want you to register for the ADA's Clinical Update Conference. And this will be taking place January 31st through February 2nd in Orlando, Florida. It's a hybrid option also to join the program virtually. And you can find the link to register in the chat box. Also, the ADA's 85th Scientific Sessions will be held on June 20th through the 23rd in Chicago. As an ADA scholar, you can receive complimentary hotel and registration to attend. And finally, be sure to apply for the 2025 ADA Scholars Program to attend the in-person program at Scientific Sessions and have access to other educational opportunities like today's session. Thank you again to the Leona M. and Harry B. Helmsley Charitable Trust for the support for today's program. This concludes our program today. Thank you again for your time. And we look forward to connecting with you in person at the ADA Scholars Program in Chicago this June. Have a good one.

non-nutritive sweeteners

GLP-1 medications

glycemic control

ADA conferences

professional development